Detalhe da pesquisa
1.
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol
; 22(1): 22-33.e6, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716619
2.
The role of chest X-rays when screening for latent tuberculosis infection in patients with inflammatory bowel disease before starting biologic treatment.
Scand J Gastroenterol
; : 1-7, 2024 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38907722
3.
Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.
Ther Drug Monit
; 44(2): 290-300, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34387220
4.
A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
Scand J Gastroenterol
; 57(3): 274-281, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779308
5.
Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.
Scand J Gastroenterol
; 57(9): 1051-1057, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35412932
6.
Treatment to target in patients with inflammatory bowel disease. What is the evidence?
Scand J Gastroenterol
; 55(5): 528-536, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503364
7.
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
Scand J Gastroenterol
; 55(8): 884-890, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32631131
8.
Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.
Ther Drug Monit
; 41(2): 235-242, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30883516
9.
Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011.
Liver Int
; 38(3): 532-541, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28796371
10.
Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.
Scand J Gastroenterol
; 53(8): 930-937, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29987951
11.
Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Dig Dis Sci
; 63(6): 1583-1591, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29564674
12.
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
BMC Med
; 15(1): 184, 2017 10 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29032767
13.
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.
J Clin Gastroenterol
; 50(6): 483-9, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26166141
14.
Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
Gut
; 69(7): 1157-1161, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32179569
15.
Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.
Am J Gastroenterol
; 110(11): 1526-32, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26032156
16.
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Dig Dis Sci
; 60(9): 2762-70, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25673037
17.
Biosimilars for Management of Crohn Disease.
Ann Intern Med
; 170(2): 129-130, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30535358
18.
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Gut
; 63(6): 919-27, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23878167
19.
Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Am J Gastroenterol
; 109(7): 1055-64, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24796769
20.
Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Ther Drug Monit
; 35(4): 530-8, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23765033